Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

165 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Primary human immunodeficiency virus type 1 infection: clinical, virological and immunological characteristics of 75 patients (1997-2003).
Sued O, Miró JM, Alquezar A, Claramonte X, García F, Plana M, Arnedo M, de Lazzari E, Gil C, Manzardo C, Blanco JL, Martínez E, Mallolas J, Joseph J, Pumarola T, Gallart T, Gatell JM. Sued O, et al. Among authors: arnedo m. Enferm Infecc Microbiol Clin. 2006 Apr;24(4):238-44. doi: 10.1016/s0213-005x(06)73769-7. Enferm Infecc Microbiol Clin. 2006. PMID: 16725083
Effect of mycophenolate mofetil on immune response and plasma and lymphatic tissue viral load during and after interruption of highly active antiretroviral therapy for patients with chronic HIV infection: a randomized pilot study.
García F, Plana M, Arnedo M, Brunet M, Castro P, Gil C, Vidal E, Millán O, López A, Martorell J, Fumero E, Miró JM, Alcamí J, Pumarola T, Gallart T, Gatell JM. García F, et al. Among authors: arnedo m. J Acquir Immune Defic Syndr. 2004 Jul 1;36(3):823-30. doi: 10.1097/00126334-200407010-00009. J Acquir Immune Defic Syndr. 2004. PMID: 15213566 Clinical Trial.
Long-term clinical follow-up, without antiretroviral therapy, of patients with chronic HIV-1 infection with good virological response to structured treatment interruption.
Florence E, García F, Plana M, Fumero E, Castro P, Lopez A, Cruceta A, Gil C, Arnedo M, Miró JM, Pumarola T, Gallart T, Gatell JM. Florence E, et al. Among authors: arnedo m. Clin Infect Dis. 2004 Aug 15;39(4):569-74. doi: 10.1086/422720. Epub 2004 Aug 3. Clin Infect Dis. 2004. PMID: 15356824
Relevance of HIV-1-specific CD4+ helper T-cell responses during structured treatment interruptions in patients with CD4+ T-cell nadir above 400/mm3.
Plana M, Garcia F, Oxenius A, Ortiz GM, Lopez A, Cruceta A, Mestre G, Fumero E, Fagard C, Sambeat MA, Segura F, Miró JM, Arnedo M, Lopalcos L, Pumarola T, Hirschel B, Phillips RE, Nixon DF, Gallart T, Gatell JM. Plana M, et al. Among authors: arnedo m. J Acquir Immune Defic Syndr. 2004 Jul 1;36(3):791-9. doi: 10.1097/00126334-200407010-00005. J Acquir Immune Defic Syndr. 2004. PMID: 15213562
Dynamics of T cells subsets and lymphoproliferative responses during structured treatment interruption cycles and after definitive interruption of HAART in early chronic HIV type-1-infected patients.
Libois A, López A, Garcia F, Castro P, Maleno MJ, García A, Climent N, Arnedo M, Gallart T, Gatell JM, Plana M. Libois A, et al. Among authors: arnedo m. AIDS Res Hum Retroviruses. 2006 Jul;22(7):657-66. doi: 10.1089/aid.2006.22.657. AIDS Res Hum Retroviruses. 2006. PMID: 16831090
165 results